Point72 Asia (Singapore) Pte. Ltd. Alnylam Pharmaceuticals, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $381 Billion
- Q1 2025
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 15,006 shares of ALNY stock, worth $4.28 Million. This represents 1.06% of its overall portfolio holdings.
Number of Shares
15,006Holding current value
$4.28 Million% of portfolio
1.06%Shares
1 transactions
Others Institutions Holding ALNY
# of Institutions
721Shares Held
111MCall Options Held
978KPut Options Held
881K-
Capital World Investors Los Angeles, CA16.7MShares$4.78 Billion0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$3.73 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.72 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.15MShares$2.04 Billion0.44% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.26 Billion0.79% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $35.1B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...